Richard Parsons

Dr. Richard Parsons


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2018 in Brain
Verified
Journal Article
Open access
PDF file
DSDaniel A Solomon
Daniel A Solomon
ASAlan Stepto
Alan Stepto
WAWing Hei Au
Wing Hei Au
YAYoshitsugu Adachi
Yoshitsugu Adachi
DDDanielle C Diaper
Danielle C Diaper
Frank HirthFrank Hirth
Frank Hirth
Accumulation and aggregation of TDP-43 is a major pathological hallmark of amyotrophic lateral sclerosis and frontotemporal dementia. TDP-43 inclusions also characterize patients with GGGGCC (G4C2) hexanucleotide repeat expansion in C9orf72 that causes the most common genetic form of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD). Functional studies in cell and animal models have identified pathogenic mechanisms including repeat-induced RNA toxicity and accumulation of G4C2-derived dipeptide-repeat proteins. The role of TDP-43 dysfunction in C9ALS/FTD, however, remains elusive. We found G4C2-derived dipeptide-repeat protein but not G4C2-RNA accumulation caused TDP-43 proteinopathy that triggered onset and progression of disease in Drosophila models of C9ALS/FTD. Timing and extent of TDP-43 dysfunction was dependent on levels and identity of dipeptide-repeat proteins produced, with poly-GR causing early and poly-GA/poly-GP causing late onset of disease. Accumulating cytosolic, but not insoluble aggregated TDP-43 caused karyopherin-α2/4 (KPNA2/4) pathology, increased levels of dipeptide-repeat proteins and enhanced G4C2-related toxicity. Comparable KPNA4 pathology was observed in both sporadic frontotemporal dementia and C9ALS/FTD patient brains characterized by its nuclear depletion and cytosolic accumulation, irrespective of TDP-43 or dipeptide-repeat protein aggregates. These findings identify a vicious feedback cycle for dipeptide-repeat protein-mediated TDP-43 and subsequent KPNA pathology, which becomes self-sufficient of the initiating trigger and causes C9-related neurodegeneration.

1 May 2009 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
BMBalpreet Matharu
Balpreet Matharu
GGGillian Gibson
Gillian Gibson
RPRichard Parsons
Richard Parsons
THThomas N. Huckerby
Thomas N. Huckerby
SMSusan A. Moore
Susan A. Moore
BABrian Austen
Brian Austen

7 March 2012 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
DHDickon M. Humphrey
Dickon M. Humphrey
RPRichard Parsons
Richard Parsons
ZLZoe N. Ludlow
Zoe N. Ludlow
TRThomas Riemensperger
Thomas Riemensperger
GEGiovanni Esposito
Giovanni Esposito
Frank HirthFrank Hirth
Frank Hirth
Mitochondrial dysfunction is commonly observed in degenerative disorders, including Alzheimer's and Parkinson's disease that are characterized by the progressive and selective loss of neuronal subpopulations. It is currently unclear, however, whether mitochondrial dysfunction is primary or secondary to other pathogenic processes that eventually lead to age-related neurodegeneration. Here we establish an in vivo Drosophila model of mitochondrial dysfunction by downregulating the catalytic subunit of mitochondrial DNA (mtDNA) polymerase in cholinergic, serotonergic and dopaminergic neurons. The resulting flies are characterized by lowered respiratory chain activity, premature aging, age-related motor deficits as well as adult onset, progressive and cell-type-specific, dopaminergic neurodegeneration. Using this model, we find that associated lethality can be partially rescued by targeting PINK1/parkin signaling or Drp1, both of which have been implicated in mitochondrial dynamics and Parkinson's disease. Bypassing mitochondrial complex III/IV deficiencies with Alternative oxidase (AOX), however, fully restores ATP levels and prevents dopaminergic neurodegeneration. In contrast, ATP levels and neurodegeneration are not rescued when mitochondrial complex I deficiencies are bypassed with NADH-Q oxidoreductase. Our results demonstrate that mtDNA-mediated mitochondrial dysfunction can cause age-related and cell-type-specific neurodegeneration which AOX is able to alleviate and indicate that AOX or its surrogates may prove useful as a therapeutic tool for limiting respiratory chain deficiencies caused by mtDNA decline in healthy aging and neurodegenerative disease.

27 April 2011 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
RPRichard Parsons
Richard Parsons
SAShylesh Aravindan
Shylesh Aravindan
AKAnusha Kadampeswaran
Anusha Kadampeswaran
EEEmily A. Evans
Emily A. Evans
KSKanwaljeet K. Sandhu
Kanwaljeet K. Sandhu
DRDavid B. Ramsden
David B. Ramsden
NNMT (nicotinamide N-methyltransferase, E.C. 2.1.1.1) catalyses the N-methylation of nicotinamide to 1-methylnicotinamide. NNMT expression is significantly elevated in a number of cancers, and we have previously demonstrated that NNMT expression is significantly increased in the brains of patients who have died of Parkinson's disease. To investigate the cellular effects of NNMT overexpression, we overexpressed NNMT in the SH-SY5Y cell line, a tumour-derived human dopaminergic neuroblastoma cell line with no endogenous expression of NNMT. NNMT expression significantly decreased SH-SY5Y cell death, which correlated with increased intracellular ATP content, ATP/ADP ratio and Complex I activity, and a reduction in the degradation of the NDUFS3 [NADH dehydrogenase (ubiquinone) iron–sulfur protein 3] subunit of Complex I. These effects were replicated by incubation of SH-SY5Y cells with 1-methylnicotinamide, suggesting that 1-methylnicotinamide mediates the cellular effects of NNMT. Both NNMT expression and 1-methylnicotinamide protected SH-SY5Y cells from the toxicity of the Complex I inhibitors MPP+ (1-methyl-4-phenylpyridinium ion) and rotenone by reversing their effects upon ATP synthesis, the ATP/ADP ratio, Complex I activity and the NDUFS3 subunit. The results of the present study raise the possibility that the increase in NNMT expression that we observed in vivo may be a stress response of the cell to the underlying pathogenic process. Furthermore, the results of the present study also raise the possibility of using inhibitors of NNMT for the treatment of cancer.

2 February 2017 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
FLFernanda M. Lopes
Fernanda M. Lopes
LMLeonardo Lisbôa da Motta
Leonardo Lisbôa da Motta
MBMarco A. De Bastiani
Marco A. De Bastiani
BPBianca Pfaffenseller
Bianca Pfaffenseller
BABianca W. Aguiar
Bianca W. Aguiar
FKFabio Klamt
Fabio Klamt

9 September 2016 in Biochemistry
Verified
Journal Article
Closed access
MHMatthijs van Haren
Matthijs van Haren
JTJavier Sastre Toraño
Javier Sastre Toraño
DSDavide Sartini
Davide Sartini
MEMonica Emanuelli
Monica Emanuelli
RPRichard Parsons
Richard Parsons
NMNathaniel I. Martin
Nathaniel I. Martin